首要终点指标是生存期，次要指标包括肿瘤缓解、症状改善、体重变化、肝功能改善等。
Primary destination indicator is survival, secondary indicators include tumor response rate, symptoms improvement, weight change and liver function improvement.
结果：对照组大鼠肝功能改善缓慢，ALT，AST明显高于移植组（P＜0.05），移植组大鼠损伤的肝组织逐渐修复，肝功能恢复正常。
Results: The liver function of control group was slow recovery, as evidenced by significantly increased ALT and AST in serum(P<0.05).
结论拉米呋丁治疗活动性肝硬化效果良好，可使肝功能明显改善。
Conclusion Adding lamivudine has better curative effect on treating active hepatocirrhosis and improving the function of liver.
应用推荐